Tag:
Incyte
Latest Headlines
Latest Headlines
Incyte rides wave after Pfizer's FDA panel nod
Incyte's shares jumped this week after agency advisers backed approval of Pfizer's potential blockbuster JAK inhibitor for rheumatoid arthritis.
Incyte's ruxolitinib wins quick approval for blockbuster bone marrow drug
Incyte ( $INCY ) has won an accelerated FDA approval for ruxolitinib (originally dubbed INC424), its JAK1 and Jak2 inhibitor for myelofibrosis, a potentially lethal though rare bone marrow disease.
